|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Adult Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Pseudolymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunostaining showed that the majority of DLBCLs (92%, 46/50) were RanGAP1(+), while reactive lymphoid hyperplasia (n = 12) was RanGAP1(+) predominantly in germinal centers.
|
24223200 |
2013 |
|
Adult Burkitt Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Childhood Burkitt Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
B Lymphoblastic Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.
|
24223200 |
2013 |
|
Adult B Lymphoblastic Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Childhood B Lymphoblastic Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Mantle cell lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%).
|
24223200 |
2013 |
|
Machado-Joseph Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Segregation distortion of wild-type alleles at the Machado-Joseph disease locus: a study in normal families from the Azores islands (Portugal).
|
18286225 |
2008 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that antioxidant defence is altered in the schizophrenic hippocampus and suggest that segregation distortion, of schizophrenia susceptibility genes, may be a possible causative factor in the high incidence of schizophrenia.Molecular Psychiatry (2000) 5, 85-90.
|
10673773 |
2000 |
|
Immunoglobulin A deficiency (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition.
|
10090895 |
1999 |
|
Claw hand
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Fine mapping of the split-hand/split-foot locus (SHFM3) at 10q24: evidence for anticipation and segregation distortion.
|
10330351 |
1999 |
|
Split foot
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Fine mapping of the split-hand/split-foot locus (SHFM3) at 10q24: evidence for anticipation and segregation distortion.
|
10330351 |
1999 |
|
Dentatorubral-Pallidoluysian Atrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, the segregation ratio of single sperm with an expanded allele to ones with a normal allele is not statistically different ( P = 0.161) from the expected 1:1 segregation ratio, and thus segregation distortion of expanded alleles in meiosis in male patients with DRPLA was not demonstrated.
|
9949204 |
1999 |
|
Learning Disabilities
|
0.010 |
Biomarker
|
disease |
BEFREE |
FRAXA and FRAXE: evidence against segregation distortion and for an effect of intermediate alleles on learning disability.
|
9435259 |
1998 |
|
POLYDACTYLY, POSTAXIAL
|
0.010 |
Biomarker
|
disease |
BEFREE |
Segregation distortion in the offspring of Afro-American fathers with postaxial polydactyly.
|
7726178 |
1995 |
|
Progressive cone-rod dystrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic linkage of cone-rod retinal dystrophy to chromosome 19q and evidence for segregation distortion.
|
8162077 |
1994 |
|
Cone-Rod Dystrophy 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of a large cone-rod dystrophy pedigree suggested that inheritance within the family was influenced by meiotic drive (p = 0.008), a rare segregation distortion in human genetics.
|
8162077 |
1994 |
|
Cone-Rod Dystrophies
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of a large cone-rod dystrophy pedigree suggested that inheritance within the family was influenced by meiotic drive (p = 0.008), a rare segregation distortion in human genetics.
|
8162077 |
1994 |
|
Rod-Cone Dystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of a large cone-rod dystrophy pedigree suggested that inheritance within the family was influenced by meiotic drive (p = 0.008), a rare segregation distortion in human genetics.
|
8162077 |
1994 |
|
Cystic Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Single sperm typing can address questions about segregation distortion in man, and it is unlikely that sex ratio distortion for CF carriers is due to events which occur pre-fertilisation.
|
7684944 |
1993 |